Xenon Pharmaceuticals Inc. (XENE) DCF Valuation

Xenon Pharmaceuticals Inc. (XENE) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Xenon Pharmaceuticals Inc. (XENE) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Xenon Pharmaceuticals Inc.'s (XENE) financial outlook with expertise! This (XENE) DCF Calculator provides pre-filled financial data and allows you to customize revenue growth, WACC, margins, and other critical assumptions to align with your predictions.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 6.8 32.2 18.4 9.4 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 371.02 -42.68 -48.83 -100 -22.88 -22.88 -22.88 -22.88 -22.88
EBITDA -39.8 -28.0 -78.1 -127.5 -210.5 .0 .0 .0 .0 .0
EBITDA, % -582.15 -86.94 -423.53 -1351.7 100 -57.39 -57.39 -57.39 -57.39 -57.39
Depreciation .4 .6 .9 1.6 3.5 .0 .0 .0 .0 .0
Depreciation, % 6.28 2 4.91 17.21 100 26.08 26.08 26.08 26.08 26.08
EBIT -40.2 -28.6 -79.0 -129.1 -214.1 .0 .0 .0 .0 .0
EBIT, % -588.43 -88.94 -428.45 -1368.91 100 -57.79 -57.79 -57.79 -57.79 -57.79
Total Cash 141.4 177.0 551.8 592.1 638.1 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .8 1.8 2.8 1.0 .9
Account Receivables, % 11.91 5.66 15 10.45 100
Inventories .0 -1.8 -2.8 -1.0 .0 .0 .0 .0 .0 .0
Inventories, % 0 -5.66 -15 -10.45 100 13.78 13.78 13.78 13.78 13.78
Accounts Payable 2.5 3.0 3.8 8.5 8.6 .0 .0 .0 .0 .0
Accounts Payable, % 36.21 9.45 20.74 90 100 51.28 51.28 51.28 51.28 51.28
Capital Expenditure -1.2 -2.6 -2.1 -2.9 -5.6 .0 .0 .0 .0 .0
Capital Expenditure, % -18.16 -8.2 -11.12 -30.68 100 -13.63 -13.63 -13.63 -13.63 -13.63
Tax Rate, % 0.15984 0.15984 0.15984 0.15984 0.15984 0.15984 0.15984 0.15984 0.15984 0.15984
EBITAT -40.2 -28.4 -79.0 -129.3 -213.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -39.3 -29.0 -79.3 -125.9 -216.6 -7.7 .0 .0 .0 .0
WACC, % 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33 10.33
PV UFCF
SUM PV UFCF -7.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -7
Net Debt -138
Equity Value 131
Diluted Shares Outstanding, MM 67
Equity Value Per Share 1.95

What You Will Get

  • Real Xenon Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Xenon Pharmaceuticals Inc. (XENE).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Xenon’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specifically for Xenon Pharmaceuticals Inc. (XENE).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your financial assessments.

Key Features

  • Comprehensive XENE Data: Pre-loaded with Xenon Pharmaceuticals' historical performance and future projections.
  • Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
  • Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined parameters.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
  • User-Friendly Interface: Intuitive, organized, and suitable for both industry experts and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Xenon Pharmaceuticals Inc. (XENE) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Xenon Pharmaceuticals Inc. (XENE)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Xenon Pharmaceuticals Inc. (XENE)?

  • User-Friendly Interface: Crafted to cater to both novice users and seasoned professionals.
  • Customizable Inputs: Adjust parameters effortlessly to fit your financial analysis needs.
  • Real-Time Valuation: Watch as changes in inputs instantly reflect on Xenon’s valuation.
  • Pre-Loaded Data: Comes equipped with Xenon’s latest financial information for swift evaluations.
  • Endorsed by Experts: A preferred tool among investors and analysts for strategic decision-making.

Who Should Use This Product?

  • Pharmaceutical Students: Understand drug development processes and apply them using real-world data.
  • Researchers: Integrate advanced models into studies or clinical research.
  • Investors: Validate your investment strategies and evaluate valuation metrics for Xenon Pharmaceuticals Inc. (XENE).
  • Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
  • Healthcare Entrepreneurs: Discover how large pharmaceutical companies like Xenon are evaluated and analyzed.

What the Template Contains

  • Preloaded XENE Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.